doi:

DOI: 10.3724/SP.J.1123.2018.06032

Chinese Journal of Chromatography (色谱) 2019/37:1 PP.100-110

Impurity profile of macitentan in tablet dosage form using a stability-indicating high performance liquid chromatography method and forced degradation study


Abstract:
Macitentan (MAC) is a pulmonary arterial hypertension (PAH) drug marketed as a tablet and often has stability issues in the final dosage form. Quantitative determination of MAC and its associated impurities in tablet dosage form has not been previously reported. This study quantified impurities present in Macitentan tablets using a binary solvent-based gradient elution method using reversed phase-high performance liquid chromatography. The developed method was validated per International Conference on Harmonization (ICH) guidelines and the drug product was subjected to forced degradation studies to evaluate stability. The developed method efficiently separated the drug and impurities (48 min) without interference from solvents, excipients, or other impurities. The developed method met all guidelines in all characteristics with recoveries ranging from 85%-115%, linearity with r2 ≥ 0.9966, and substantial robustness. The stability-indicating nature of the method was evaluated using stressed conditions (hydrolysis:1 N HCl at 80℃/15 min; 1 N NaOH at 25℃/45 min; humidity stress (90% relative humidity) at 25℃ for 24 h, oxidation:at 6% (v/v) H2O2, 80℃/15 min, thermolysis:at 105℃/16 h and photolysis:UV light at 200 Wh/m2; Fluorescent light at 1.2 million luxh). Forced degradation experiments showed that the developed method was effective for impurity profiling. All stressed samples were assayed and mass balance was>96%. Forced degradation results indicated that MAC tablets were sensitive to hydrolysis (acid and alkali) and thermal conditions. The developed method is suitable for both assay and impurity determination, which is applicable to the pharmaceutical industry.

Key words:reverse phase-high performance liquid chromatography (RP-HPLC),stability-indicating method,forced degradation study,binary solvent gradient,endothelin receptor antagonist (ERA),pulmonary arterial hypertension (PAH),macitentan (MAC),impurity profiling

ReleaseDate:2019-01-31 09:03:39



[1] OPSUMIT® (Macitentan) Tablets, Label.[2018-05-31]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204410s000lbl.pdf

[2] Hong I S, Coe H V, Catanzaro L M, et al. Ann Pharmacother, 2014, 48(4):1

[3] Iglarz M, Binkert C, Morrison K, et al. J Pharmacol Exp Ther, 2008, 327:736

[4] Patricia N S, Paul L M V G, Atef H, et al. Eur J Clin Pharmacol, 2011, 67:977

[5] Wikizero, Macitentan.[2018-05-31]. https://www.wikizero.com/en/Macitentan

[6] Gatfield J, Mueller G C, Sasse T, et al. PLoS One, 2012, 7(10):e47662

[7] Olivier S, Nicholas W M. Eur Respir Rev, 2012, 21(126):321

[8] Actelion Pharmaceuticals Australia Pty Ltd. Australian Public Assessment Report for Macitentan Proprietary Product Name.[2018-05-31]. https://www.tga.gov.au/sites/default/files/auspar-macitentan-140428.pdf

[9] Martin H B, Christoph B, Christoph B, et al. J Med Chem, 2012, 55:7849

[10] Kunal M J, Raghunath B T, Vijayavitthal T M, et al. IJSRST, 2017, 3(10):137

[11] ICH Q3A(R2) Impurities in New Drug Substances.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3A_R2/Step4/Q3A_R2__Guideline.pdf

[12] European Medicines Agency. Guideline on Setting Specifications for Related Impurities in Antibiotics, Final.[2018-05-31]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129997.pdf

[13] ICH Q3B (R2) Impurities in New Drug Products.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q3B_R2/Step4/Q3B_R2__Guideline.pdf

[14] Nandini R P, Seema S S. Der Pharma Chemica, 2013, 5(4):274

[15] Prabha S, Devarakonda V R, Raju V K V, et al. J Pharm Biomed Anal, 2010, 52:142

[16] Satyanarayana R T, Vishweshwari K O, Ganesh V, et al. JPA, 2012, 2(4):272

[17] Esen B A, Yucel Y, Cagan A, et al. J Pharm Biomed Anal, 2017, 136:1

[18] Li C Y, Lan G J, Jiang J Y, et al. Chromatographia, 2015, 78:825

[19] Siva K R, Sravan K K V, Kondareddy L, et al. J Chromatogr Sci, 2018; 56(5):383

[20] Saurabh P, Preeti P, Durgesh M, et al. Braz J Pharm Sci, 2013, 49(1):175

[21] Lakshmi D, Hitesh K P, Praveen M, et al. J Pharm Drug Deliv Res, 2016, 5(6)

[22] Aziz U, Syed S A, Santosh K S, et al. IAJPR, 2014, 4:3836

[23] Manzoor A, Deepak B M, Satishkumar S A, et al. WJPPS, 2015, 4:881

[24] Oliver K, Manuel H, Felix H, et al. Eur J Pharm Sci, 2009, 38(4):384

[25] Yu L, Zhou Y, He X, et al. J Chromatogr B, 2015, 1002:358

[26] Alexander T, Paivi A, Ruben D K, et al. J Pharmacol Exp Ther, 2014, 350:130

[27] Jin Z, Peiwu G, Xinhua L, et al. IJCEM, 2015, 8:18420

[28] Shirin B, Paivi A, Marie-Claude H, et al. AAPS J, 2012, 14(1):68

[29] Wu B, Li X, Cui H, et al. Anhui Medical and Pharmaceutical Journal, 2017, 21(2):248

[30] Mohit T, Debasish S, Gananadhamu S, et al. Chromatographia, 2018, 81(3):525

[31] ICH Q1A (R2) Stability Testing of New Drug Substances and Products.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline.pdf

[32] Llyod R S, Joseph J K, Joseph G L. Practical HPLC Method Development. 2nd ed. Hoboken:John Wiley and Sons, 2010

[33] Q2(R1) Validation of Analytical Procedures:Text and Methodology, 1996.[2018-05-31]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf

[34] United States Pharmacopeia. USP <1225> Validation of Compendial Procedures. USP 38, 2018, 1445